Every 10-Q that Bio-Rad Laboratories, Inc. (BIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIO filings page.
Bio-Rad Laboratories reported Q2 2026 net sales of $651.0 million, essentially flat year over year, with gross margin at 53.1%. Life Science sales declined to $252.0 million while Clinical Diagnostics grew to $399.0 million, leaving consolidated operating income at $72.6 million.
Non-operating items dominated results. A $458.0 million gain from changes in the fair value of equity securities and a loan receivable, largely related to the Sartorius position, lifted Q2 net income to $371.4 million, or $13.85 per diluted share. For the first half, however, a $280.2 million fair-value loss on these assets contributed to a net loss of $155.7 million despite $106.7 million of income from operations.
Liquidity remained strong with $1.62 billion in cash, cash equivalents and short-term investments and no borrowings under a $200.0 million revolving credit facility. The $400 million 3.3% Senior Notes due 2027 are now classified as current, and the company indicates sufficient resources to repay or potentially refinance them. A subsequent restructuring plan announced for July 2026 is expected to incur $80 million to $90 million of pre-tax charges through 2027.
Bio-Rad Laboratories reported Q1 2026 results showing stable sales but a large accounting loss driven by its equity holdings. Net sales were $592.1 million, up slightly from $585.4 million a year earlier, with gross margin steady at 52.3%.
Operating income improved to $34.1 million from $23.7 million, but a $738.2 million loss from changes in fair value of equity securities and a loan receivable, including a $727.7 million holding loss on its Sartorius investment, led to a net loss of $527.1 million versus prior-year net income of $64.0 million.
Cash from operations was $108.1 million, and Bio-Rad ended the quarter with $507.2 million in cash and cash equivalents plus $1,057.5 million in short-term investments. The company repurchased 176,257 Class A shares for $47.8 million and still has $237.1 million available under its 2023 share repurchase program, while carrying $1.2 billion of Senior Notes due 2027 and 2032.
Bio‑Rad Laboratories reported Q3 2025 net sales of $653.0 million, roughly flat year over year, with income from operations of $65.3 million. A $495.3 million loss from the change in fair value of equity securities and a tax benefit of $89.2 million drove a net loss of $341.9 million for the quarter.
For the first nine months, net sales were $1,890.0 million and net income $39.9 million. Operating cash flow reached $367.3 million. The company repurchased $295.5 million of shares year to date.
Bio‑Rad closed the acquisition of Stilla Technologies on June 30, 2025 for total preliminary consideration of $257.7 million, including cash paid to sellers, debt repayments, escrow, and $28.6 million of contingent consideration (up to $50.0 million tied to milestones). Cash and cash equivalents were $395.8 million and short‑term investments $1,022.8 million as of September 30, 2025. Long‑term debt consisted of $1.2 billion of senior notes. The fair value loss related to the Sartorius AG stake was $505.1 million in Q3.